If you liked this article you might like

AstraZeneca Tops Earnings Estimate, But Crestor and Onglyza Sales Slow
What to Expect From European Pharmaceuticals' First Quarter Results
Europe Benchmarks Pare Losses but Caution Remains
Mylan Has Been Pounded, but the Pain May be Far from Over